The latest episode of "The Readout LOUD" discusses the acquisition of Kelonia Therapeutics, a CAR-T biotech that was on the brink of closure, by Eli Lilly for $3.25 billion, and examines the strategies drugmakers are employing to increase prescription rates through partnerships with telehealth providers.
The most valuable insight for someone tracking healthtech and biotech is the acquisition of Kelonia Therapeutics, a CAR-T biotech, by Eli Lilly for $3.25 billion. This highlights a significant turnaround for a company that nearly ran out of funds multiple times, underscoring the potential for strategic investments and M&A activities in the biotech sector, particularly in advanced therapies like CAR-T. Additionally, the mention of drugmakers collaborating with telehealth provider Prescribery to drive prescriptions suggests emerging trends in digital health partnerships that could be leveraged for market expansion.